New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
08:12 EDTLGNDLigand signs multi-program Captisol license agreement with Avion Pharmaceuticals
Ligand Pharmaceuticals Incorporated announces the signing of a commercial license agreement with Avion Pharmaceuticals, LLC for the development and commercialization of four Captisol-enabled programs. Under the terms of the agreement, Ligand is entitled to receive an up-front payment, and is eligible to receive revenue from Captisol material sales, potential milestone payments, and royalties on future net sales of the products containing Captisol.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
16:07 EDTLGNDLigand sees FY16 adjusted EPS $3.37-$3.42, consensus $3.41
Subscribe for More Information
16:02 EDTLGNDLigand reports Q4 EPS 66c, consensus 65c
Subscribe for More Information
February 2, 2016
09:01 EDTLGNDLigand enters into OmniAb platform license pact with Tizona
Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Tizona Therapeutics, Inc. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use